Mural Oncology plc (MURA) Earnings History
Net Loss4 years of earnings data (2021–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Mural Oncology plc (MURA) Earnings Overview
As of June 28, 2026, Mural Oncology plc (MURA) reported trailing twelve-month net income of -$119M, reflecting +39.0% year-over-year growth. The company earned $-6.88 per diluted share over the past four quarters.
Looking at the long-term picture, MURA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$129M in fiscal 2024, representing a new all-time high.
Mural Oncology plc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTR (-$158M net income, -297.1% margin), CLDX (-$284M net income, -17253.3% margin), IMVT (-$506M net income), MURA has comparable earnings metrics. Compare MURA vs NKTR →
MURA Earnings vs Peers
Earnings metrics vs comparable public companies
MURA Historical Earnings Data (2021–2024)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$129M | +38.0% | -$138M | $-7.58 | - | - |
| 2023 | -$207M | -9.3% | -$195M | $-12.43 | - | - |
| 2022 | -$190M | -8.2% | -$185M | $-11.37 | - | - |
| 2021 | -$175M | - | -$175M | $-10.51 | - | - |
Download Data
Export MURA earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MURA — Frequently Asked Questions
Quick answers to the most common questions about buying MURA stock.
What is MURA earnings per share (EPS)?
MURA trailing twelve-month (TTM) diluted EPS is $-6.88, reflecting +39.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2021 to 2024 is available in the table on this page.
What is Mural Oncology plc's net income?
Mural Oncology plc (MURA) trailing twelve-month net income is $-119M as of 2024. Earnings grew +39.0% year-over-year.
Is MURA profitable?
MURA is not currently profitable on a TTM basis, reporting a net loss of $-119M. Net margin is N/A. Investors should monitor for a return to profitability.
What is MURA's earnings growth rate?
MURA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2021 to 2024.
What are MURA's profit margins?
Mural Oncology plc net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -63.6%.
Is MURA growing earnings?
Yes, MURA earnings are accelerating — EPS growth of +39.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-119M. Earnings momentum is strengthening.
What was MURA's best earnings year?
Mural Oncology plc's highest annual net income on record is $-129M, achieved in fiscal year 2024. Earnings history on this page spans 2021 to 2024 and includes all annual and quarterly figures.
What were MURA's earnings last quarter?
MURA's most recent reported quarter was Q3 2025. Net income was $-4M with diluted EPS of $-0.21. For a full breakdown of all quarters, see the quarterly earnings table on this page.